MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes

Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on October 24.

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stocktwits.com)